Category Archives: 2018 17th International Kidney Cancer Symposium

Trump National Doral Miami Hotel, Miami, FL November 2-3, 2018

Cost-Effective Biomarkers Ready at our fingertips

Cell-free DNA (cfDNA)

RCC Profiling

An Empirical Approach to Dissect the TME in RCC

The impact of the stool microbiome in RCC

Single Cell RNA-Sequencing in RCC

Renal mass biopsy in 2018: When, where and how?

Emerging Ablative Technologies – Whats New And Is It Better?

Overdiagnosis and the Harms of Overtreatment of Renal Cell Carcinoma

The Radiological Biopsy: Are we there yet? Imaging based renal mass diagnosis

Pro vs Con for Enucleation

Enucleation of Renal Mass: Why Would You Not Keep Your Distance?

Laparoscopic Vs Robotic Radical Nephrectomy: What are the Costs and Benefits?

RCC: Putting Frontline Combination Data into Perspective

Metastatic Renal Cell Cancer: Who Deserves Monotherapy?

Beyond Checkpoint 

Tayloring Therapy: Therapy Intensification and Discontinuation

Phase II trial of intermittent nivolumab

Ongoing Clinical Trial Update: A Pilot Study of Pre-surgical Tremelimumab with or without Tissue Cryoablation

Rationally Targeting the Bone with Radium Plus Cabozantinib

Treatment-Free Survival Following Discontinuation of First-Line Nivolumab Plus Ipilimumab or Sunitinib


Safety and efficacy of checkpoint inhibitors

CheckMate 214 Retrospective Analyses

An Evaluation of the Role of Cytoreductive Nephrectomy in Patients with Sarcomatoid RCC

Neoadjuvant PD1 Blockade to Prime the Immune System

Combination Checkpoint Blockade with Surgery

What is the Next Cytoreductive Surgical Trial?

Creating Synergy in RCC: Collaborative Approaches to Value

Engaging Clinical Trialists in the Community Setting

Exploiting oncometabolite-induced DNA repair defects

Adenosine Pathway Inhibitors

Neovax: From Translation to Bedside

Targeting Epigenetics and Chromatin Remodeling Genes

Neovax: From Translation to Bedside

Novel metabolic insights into RCC biology and immune response

Secreted PD-L1 Splice Variant that Covalently Dimerizes and Mediates Immunosuppression

Targeting Vulnerabilities Arising from Dysregulated Histone Demethylase Function in Kidney Cancer

Whole Body MRI for Detection of Renal Cell Carcinoma Osseous Metastases

LARCG Latin American Renal Cancer Group


Phase 1b study (COSMIC-021) of cabozantinib in combination with atezolizumab:
Results of the dose-escalation stage in 
patients with treatment-naïve advanced 
renal cell carcinoma

Second-Line VEGFR TKI Outcomes After First-Line Immune Checkpoint Blockade in Metastatic Renal Cell Carcinoma

Ipilimumab plus Nivolumab as Salvage Therapy in Patients with Checkpoint Inhibitor-Refractory Metastatic Renal Cell Carcinoma